The success of Sildenafil initially fueled a boom for pharma, nevertheless recent developments present a complicated scenario for shareholders. Off-patent versions are eating into profits, and persistent patent https://dianezrld859247.activosblog.com/39765715/sildenafil-and-pharma-a-risky-play